Company / PP&E (Net)
ARS Pharmaceuticals, Inc. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$2.5M
FY2025
5-year range
$72.0K / $2.5M
FY2021-FY2025
Trend
+131.2%
vs FY2024
Sector context
#127 of 193
Health Care
What the data says
At $2M, ARS Pharmaceuticals, Inc.'s pp&e (net) ranks #127 of 193 in the Health Care sector. PP&E (Net) has increased for 4 consecutive years, from $72,000 in FY2021 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +8.8%.
Improved from $574,000 to $2M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +95.7%
- 5-Year CAGR
- +8.8%
- 10-Year CAGR
- -
Sector benchmark
#127 of 193 in Health CareTop 66% of 193This company $2.5M Sector average $777.6M
▼
-99.7% below sector average
Key checks
Key Insights
- ARS Pharmaceuticals, Inc.'s pp&e (net) has grown for 4 consecutive years.
- 5-year CAGR of +8.8%, indicating consistent growth.
- In FY2025, pp&e (net) increased 131.2% year-over-year.
- Ranks #127 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.5M | +131.2% |
| FY2024 | $1.1M | +85.7% |
| FY2023 | $574.0K | +74.5% |
| FY2022 | $329.0K | +356.9% |
| FY2021 | $72.0K | -95.6% |
| FY2020 | $1.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026